<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1166">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04344782</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200389-7</org_study_id>
    <nct_id>NCT04344782</nct_id>
  </id_info>
  <brief_title>Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort</brief_title>
  <acronym>CORIMMUNO-BEVA</acronym>
  <official_title>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19- BEVA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bevacizumab, ZERIBEV® (Pfizer)/AVASTIN® (Roche) 25 mg/ml ®, is a recombinant humanised
      monoclonal IgG1 antibody It seems interesting to use bevacizumab in severe patients infected
      with SARS-CoV-2 requiring hospitalization in conventional unit or in ICU.

      This protocol CORIMUNO19-BEVA will evaluate the efficacy and safety of AVASTIN®/ ZERIBEV®
      (bevacizumab) COVID-19 patients hospitalized in conventional units.

      This phase 2 randomized clinical trial aimed at evaluating the efficacy and safety of
      AVASTIN®/ ZERIBEV® (bevacizumab) alone versus standard of care (SoC) in patients hospitalized
      in conventional units.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of surviving patients without need for intubation for respiratory support</measure>
    <time_frame>day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Saturation of Oxygen in the blood (SaO2)</measure>
    <time_frame>day 14</time_frame>
    <description>value of a healthy individual occurs between 95 - 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial oxygen partial pressure (paO2)</measure>
    <time_frame>day 14</time_frame>
    <description>value of a healthy individual occurs between 75-100 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of arterial oxygen partial pressure to fractional inspired oxygen (paO2/FiO2)</measure>
    <time_frame>day 14</time_frame>
    <description>Normal level should be &gt;500 Index of severity of acute respiratory distress syndrome (ARDS) mild if 200-300 moderate if 100-200 severe if &lt; 200</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT-scan score</measure>
    <time_frame>day 14</time_frame>
    <description>based on a Likert scale with scores ranging from 1 to 5 (1-definitely no; 2-probably no; 3-equivocal; 4-probably yes; 5-definitely yes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dyspnea</measure>
    <time_frame>day 28</time_frame>
    <description>measured on an visual analog scale (VAS), ranging from 0 (no dyspnea) to 10 (major dyspnea)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>day 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>admissionn to the intensive care unit (ICU)</measure>
    <time_frame>day 14 and day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of mechanical ventilation</measure>
    <time_frame>day 14 and day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital length of stay</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse event</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF plasma concentration</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>COVID19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab Injection</intervention_name>
    <description>Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients Requiring more than 3L/min of oxygen

          -  WHO progression scale = 5 to 8

        Exclusion Criteria:

          -  Patients in 9 WHO progression class

          -  Patients with exclusion criteria to the CORIMUNO-19 cohort.

          -  Hypersensitivity to Bevacizumab or to any of their excipients.

          -  Pregnancy

          -  Active Cancer with undergoing treatment

          -  Oxygen patient requiring long-term oxygen before hospitalization

          -  Patient already included in a therapeutic trial; however, inclusion should be
             discussed case by case with the trial coordinator.

          -  Contraindication to bevacizumab, risk of bleeding especially hemoptysis, active venous
             or arterial thromboembolic disease and recent surgery.

          -  Hypersensitivity to the active substance or one of the excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacques Cadranel, MD PhD</last_name>
    <phone>1 56 01 66 73</phone>
    <phone_ext>33</phone_ext>
    <email>jacques.cadranel@aphp.fr</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

